Nivolumab-induced bullous pemphigoid managed without drug withdrawal
The widespread use of anti-programmed cell death receptor-1 (PD-1) agents has shed light to unusual immune-related adverse effects, especially affecting the skin. We report a case of bullous pemphigoid secondary to nivolumab therapy for metastatic renal carcinoma with a previously unreported complet...
Saved in:
Main Authors: | Mónica Munera-Campos (Author), Adrià Plana-Pla (Author), Noelia Rivera (Author), Aram Boada (Author), Carlos Ferrándiz (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nivolumab-induced oral and cutaneous bullous pemphigoid: A case report
by: Sturque Julie, et al.
Published: (2019) -
Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
by: Yuka Maya, MD, et al.
Published: (2020) -
A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal
by: Katerina Svigos, BA, et al.
Published: (2021) -
Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid
by: Mika M. Tabata, BS, et al.
Published: (2020) -
Bullous pemphigoid
by: Denise Miyamoto, et al.